1. van der Laan JW, Benson CT, Janssens W, Bos J, Stahl E, Brady JT, Wändel-Liminga U, Corriol-Rohou S, Forster R, Hartmann A, Pertel PE, Robertson SM, Silva-Lima B, Malik RE, Chibout SD. Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018. Ther Innov Regul Sci. 2020 Mar;54(2):462-467. doi: 10.1007/s43441-019-00077-3. Epub 2020 Jan 6.
  2. Glerum PJ, Maliepaard M, de Valk V, Scholl JHG, van Hunsel FPAM, van Puijenbroek EP, Burger DM, Neef K. Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands. Clin Transl Sci. 2020 Feb 12. doi: 10.1111/cts.12746.
  3. de Vries ST, Denig P, Ekhart C, Mol PGM, van Puijenbroek EP. Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. Drug Saf. 2020 Feb 11. doi: 10.1007/s40264-020-00913-8.
  4. Maliepaard M, Taams AC, Sung C, Poh J, Yu Y.  Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation? Pharmaceut Med. 2019 Oct;33(5):407-416. doi: 10.1007/s40290-019-00302-2.
  5. Pétavy F, Guizzaro L, Dos Reis IA, Teerenstra S, Roes KCB. Beyond "Intent-to-treat" and "Per protocol": Improving assessment of treatment effects in clinical trials through the specification of an estimand. Br J Clin Pharmacol. 2019 Dec 27. doi: 10.1111/bcp.14195.
  6. van Riet-Nales D, Donkerbroek L, Nicia A, Oussoren C, de Boer A, van den Bemt B. The development of a test battery to assess the hand-eye functions relevant in predicting easy and accurate tablet subdivision in older people: A pilot study. Br J Clin Pharmacol. 2019 Dec 25. doi: 10.1111/bcp.14201.
  7. van der Plas RM, Hoefnagel MHN, Hillege HL, Roes KCB. Pragmatic rules for comparability of biological medicinal products. Biologicals. 2020 Jan;63:97-100. doi: 10.1016/j.biologicals.2019.11.002. Epub 2019 Dec 11.
  8. Yu Y, Maliepaard M. Comment on "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?" Clin Pharmacokinet. 2020 Feb;59(2):281-282. doi: 10.1007/s40262-019-00850-5.
  9. Arlett P, Straus S, Rasi G. Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther. 2020 Jan;107(1):89-91. doi: 10.1002/cpt.1689. Epub 2019 Nov 22. 
  10. Weersink RA, Abadier M, de Boer A, Taxis K, Borgsteede SD.  Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients. Br J Clin Pharmacol. 2019 Nov 22. doi: 10.1111/bcp.14177.
  11. Hulshof TA, Zuidema SU, Gispen-de Wied CC, Luijendijk HJ. Run-in periods and clinical outcomes of antipsychotics in dementia: A meta-epidemiological study of placebo-controlled trials. Pharmacoepidemiol Drug Saf. 2020 Feb;29(2):125-133. doi: 10.1002/pds.4903. Epub 2019 Nov 15. Review.
  12. Yauk CL, Harrill AH, Ellinger-Ziegelbauer H, van der Laan JW, Moggs J, Froetschl R, Sistare F, Pettit S.  A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies. Regul Toxicol Pharmacol. 2020 Feb;110:104526. doi: 10.1016/j.yrtph.2019.104526. Epub 2019 Nov 11.
  13. Sato Y, Bando H, Di Piazza M, Gowing G, Herberts C, Jackman S, Leoni G, Libertini S, MacLachlan T, McBlane JW, Pereira Mouriès L, Sharpe M, Shingleton W, Surmacz-Cordle B, Yamamoto K, van der Laan JW. Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider. Cytotherapy. 2019 Nov;21(11):1095-1111. doi: 10.1016/j.jcyt.2019.10.001. Epub 2019 Nov 9. Review.
  14. Zijp TR, Mol PGM, Touw DJ, van Boven JFM. Smart Medication Adherence Monitoring in Clinical Drug Trials: A Prerequisite for Personalised Medicine? EClinicalMedicine. 2019 Aug 27;15:3-4. doi: 10.1016/j.eclinm.2019.08.013. eCollection 2019 Oct.